ycbd20250115_8k.htm
false
0001644903
0001644903
2025-01-15
2025-01-15
0001644903
ycbd:CommonStockCustomMember
2025-01-15
2025-01-15
0001644903
ycbd:SeriesACumulativeConvertiblePreferredStock8CustomMember
2025-01-15
2025-01-15
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 15, 2025
|
cbdMD, Inc.
|
|
(Exact name of registrant as specified in its charter)
|
|
North Carolina
|
|
001-38299
|
|
47-3414576
|
|
(State or other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
2101 Westinghouse Blvd., Suite A
Charlotte, NC 28273
(704)445-3060
(Address and telephone number, including area code, of registrant’s principal executive offices)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
| |
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
| |
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
| |
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act: None.
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
Common Stock
|
YCBD
|
NYSE American
|
|
8% Series A Cumulative Convertible Preferred Stock
|
YCBD PR A
|
NYSE American
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
cbdMD, Inc. (the “Company”) issued a press release on January 15, 2025 disclosing that on January 14, 2025 the remaining outstanding Senior Secured Convertible Notes in the amount of approximately $56,000 were converted by the holders of such notes into shares of the Company’s common stock. As of January 14, 2025, the Company has issued and outstanding 6,262,833 shares of common stock. A copy of the press release is included herewith as Exhibit 99.1, which is incorporated by reference into this Item 8.01.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit
Number
|
|
Exhibit
|
|
99.1
|
|
|
|
104
|
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
cbdMD, Inc.
|
|
| |
|
|
|
|
Date: January 15, 2025
|
By:
|
/s/ T. Ronan Kennedy
|
|
| |
|
Name: T. Ronan Kennedy
|
|
| |
|
Title: Chief Executive Officer and Chief Financial Officer
|
|